Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

ClinicalTrials.gov ID: NCT04583592

Public ClinicalTrials.gov record NCT04583592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients

Study identification

NCT ID
NCT04583592
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sagent Pharmaceuticals Inc.
Industry
Enrollment
295 participants

Conditions and interventions

Conditions

Interventions

  • Camostat Mesilate Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 8, 2020
Primary completion
Mar 30, 2021
Completion
Mar 30, 2021
Last update posted
Jan 17, 2022

2020 – 2021

United States locations

U.S. sites
21
U.S. states
10
U.S. cities
19
Facility City State ZIP Site status
Palmtree Clinical Research, Inc. (Site 125) Palm Springs California 92262
Synergy Healthcare, LLC (Site 124) Bradenton Florida 34208
Clinical Research of Brandon, LLC (Site 123) Brandon Florida 33511
Reliable Clinical Research, LLC (Site 100) Hialeah Florida 33012
A+ Research (Site 112) Miami Florida 33144
NextPhase Research Alliance at CANO HEALTH (Site 107) Miami Florida 33144
Ezy Medical Research (Site 106) Miami Florida 33175
Eminat LLC (Site 117) Plantation Florida 33317
Invictus Clinical Research Group, LLC (Site 101) Pompano Beach Florida 33064
Visionaries Clinical Research, LLC (Site 121) Atlanta Georgia 30318
Family Care Research (Site 114) Boise Idaho 83704
Cedar Crosse Research Center (Site 122) Chicago Illinois 60607
Massachusetts General Hospital (Site 110) Boston Massachusetts 02114
Oakland Medical Research Center (Site 108) Troy Michigan 48085
Cary Research Group (Site 111) Cary North Carolina 27518
Onsite Solutions (Site 118) Charlotte North Carolina 28208
STAT Research (Site 109) Springboro Ohio 45066
Toledo Institute of Clinical Research, Inc.(Site 105) Toledo Ohio 43617
Advanced Medical Trials (Site 104) Georgetown Texas 78628
Next Innovative Clinical Research (Site 115) Houston Texas 77021
Rio Grand Valley Clinical Research Institute (Site 120) Pharr Texas 78577

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04583592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2022 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04583592 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →